Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?
暂无分享,去创建一个
[1] L. Coupal,et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. , 1999, Archives of internal medicine.
[2] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[3] D. Redelmeier,et al. The treatment of unrelated disorders in patients with chronic medical diseases. , 1998, The New England journal of medicine.
[4] L. Coupal,et al. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. , 1998, Archives of internal medicine.
[5] S. Haffner. Management of Dyslipidemia in Adults With Diabetes , 1998, Diabetes Care.
[6] S. Haffner. Management of Dyslipidemia in Adults With Diabetes , 1998, Diabetes Care.
[7] W. Manning,et al. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. , 1997, JAMA.
[8] A. Zbrozek,et al. Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.
[9] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[10] M. Gold,et al. Panel on cost-effectiveness in health and medicine. , 1996, Medical care.
[11] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[12] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[13] G. Thorgeirsson,et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. , 1996, Circulation.
[14] M A Hlatky,et al. Task force 6: cost effectiveness of assessment and management of risk factors , 1996 .
[15] V. Fuster,et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. , 1996, Journal of the American College of Cardiology.
[16] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[17] C. Furberg,et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. , 1995, Circulation.
[18] Resource Utilization and Costs of Care in the Diabetes Control and Complications Trial , 1995, Diabetes Care.
[19] Toni Martin,et al. Physician and Patient Prevention Practices in NIDDM in a Large Urban Managed-Care Organization , 1995, Diabetes Care.
[20] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[21] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[22] L. Coupal,et al. Serum lipid screening to identify high-risk individuals for coronary death. The results of the Lipid Research Clinics prevalence cohort. , 1994, Archives of internal medicine.
[23] J. Mckenney,et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.
[24] J. Huttunen,et al. Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study , 1992, Diabetes Care.
[25] L. Goldman,et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. , 1991, JAMA.
[26] R B D'Agostino,et al. Probability of stroke: a risk profile from the Framingham Study. , 1991, Stroke.
[27] Mckendry Jb. Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. , 1989 .
[28] Roger A. Renfrew,et al. Lipid Research Clinics Program. , 1984, JAMA.
[29] D. Jacobs,et al. Lipoprotein‐Cholesterol Distributions in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study , 1980, Circulation.
[30] L. Wilkins. Plasma Lipid Distributions in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study THE LIPID RESEARCH CLINICS PROGRAM EPIDEMIOLOGY COMMITTEE , 1979, Circulation.
[31] P. Renshaw,et al. [Detection, evaluation, and treatment of high blood cholesterol in adults]. , 2001, Revista panamericana de salud publica = Pan American journal of public health.
[32] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[33] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[34] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[35] M. A. J. Ohannesson,et al. COST EFFECTIVENESS OF SIMVASTATIN TREATMENT TO LOWER CHOLESTEROL LEVELS IN PATIENTS WITH CORONARY HEART DISEASE , 1997 .
[36] J. McKendry. Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. , 1989, Canadian journal of public health = Revue canadienne de sante publique.